earnings
confidence high
sentiment negative
materiality 0.80
Moderna Q2 net loss $0.8B, rev $142M (-41% YoY); cuts 2025 revenue guidance high end by $300M
Moderna, Inc.
2025-Q2 EPS reported
-$4.64
revenue$250,000,000
- Q2 revenue $142M (-41% YoY); GAAP net loss $0.8B ($2.13 EPS loss).
- 2025 revenue guidance narrowed to $1.5-$2.2B (high end cut $300M due to UK delivery timing shift to 2026).
- GAAP operating expenses expected $5.9-$6.1B, improved ~$400M; year-end cash ~$6B reiterated.
- Announced three FDA approvals (mNEXSPIKE for high-risk adults, Spikevax for children, mRESVIA for 18-59) and positive Phase 3 flu vaccine efficacy data.
- Restructuring: global workforce reduction of ~10%, targeting headcount under 5,000 by year-end.